A Randomized, Crossover Study to Evaluate the Overall Safety and Tolerability of Paliperidone Palmitate Injected in the Deltoid or Gluteus Muscle in Subjects With Schizophrenia The primary objectives of this study are to evaluate the safety and tolerability of: a). the deltoid muscle injection site for initiating treatment with any of 3 doses of paliperidone palmitate (50,...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Daratumumab Open label, dose-escalation safety study in Combination with Bortezomib and Dexamethasone in Patients with multiple myeloma To establish the safety profile of daratumumab when given in combination with bortezomib and dexamethasone in subjects with relapsed or refractory MM

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus To evaluate the efficacy of ustekinumab as measured by a reduction in disease activity for subjects with active SLE

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase IIa Multicenter, Randomized, Double-Blind, Placebo -Controlled, Parallel Group Study of RWJ-445380 Cathepsin-S Inhibitor in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy To assess the safety and tolerability of RWJ-445380 at doses of 100, 200, or 300 mg/day for up to 12 weeks in patients with active Rheumatoid Arthritis (RA) despite methotrexate (MTX) therapy.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomized,double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety and tolerability of RWJ333369 as adjunctive therapy in subjects with partial onset seizure Percent reduction in seizure frequency (average monthly seizure rate per 28 days) of all simple partial motor and/or complex partial, and/or secondarily generalized seizures during the double-blind tr...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Étude CR100847 : Étude de phase 2, visant à évaluer l’efficacité et la tolérance de l’ibrutinib, chez des patients ayant un lymphome à cellules du manteau en progression après un traitement par bortézomib. [essai clos aux inclusions] A venir

• Pays France
• Organes Lymphomes non hodgkinien
• Spécialités Thérapies Ciblées

A Study in Subjects with Early Alzheimer's Disease Investigating the Effects of JNJ-54861911 on Safety and Tolerability Estudio en pacientes con enfermedad de Alzheimer temprana para estudiar la seguridad y tolerabilidad de JNJ-54861911 The primary objective of this study is to investigate the longer-term safety and tolerability of JNJ-54861911 during 6 months of treatment in subjects in the early (predementia) AD spectrum. El ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study of Guselkumab in the Treatment of Participants with Moderate to Severe Plaque-Type Psoriasis with Randomized Withdrawal and Retreatment • To evaluate the efficacy of guselkumab in the treatment of subjects with moderate to severe plaque-type psoriasis. • To assess the safety and tolerability of guselkumab in subjects with moderate to...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Subjects with International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome The primary objective is to assess the clinical efficacy of siltuximab, demonstrated by a reduction in RBC transfusions to treat the anemia of MDS.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Rivaroxaban for Thromboprophylaxis in Pediatric Subjects 2 to 8 Years of Age after the Fontan Procedure Part A To characterize the single- and multiple-dose PK and PK/ PD profiles after oral rivaroxaban therapy administered to pediatric subjects 2 to 8 years of age with single ventricle physiology who ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune